Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer

Enzalutamide (MDV3100) is a second generation Androgen Receptor (AR) antagonist with proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority of treated patients, however, develop resistance and disease progression and there is a critical need to identify novel t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kregel, Steven, Chen, James L., Tom, Westin, Krishnan, Venkatesh, Kach, Jacob, Brechka, Hannah, Fessenden, Tim B., Isikbay, Masis, Paner, Gladell P., Szmulewitz, Russell Z., Vander Griend, Donald J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041979/
https://www.ncbi.nlm.nih.gov/pubmed/27036029
http://dx.doi.org/10.18632/oncotarget.8456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041979/
https://www.ncbi.nlm.nih.gov/pubmed/27036029
http://dx.doi.org/10.18632/oncotarget.8456

Ejemplares similares